{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:24:37Z","timestamp":1793381077156,"version":"4.5.0"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00520-025-10054-2","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:36:55Z","timestamp":1761629815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune checkpoint inhibitor associated lichenoid eruptions: a review of non-steroidal systemic maintenance therapies"],"prefix":"10.1007","volume":"33","author":[{"given":"Richard","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushila A.","family":"Toulmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair S.","family":"Allais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Brag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Iriarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"5","key":"10054_CR1","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29(5):3044\u20133060","journal-title":"Curr Oncol"},{"issue":"1","key":"10054_CR2","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo JA, Kimbrough EO, Lou Y (2021) Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol 14(1):45","journal-title":"J Hematol Oncol"},{"issue":"16_suppl","key":"10054_CR3","doi-asserted-by":"crossref","first-page":"11057","DOI":"10.1200\/JCO.2024.42.16_suppl.11057","volume":"42","author":"J Paul","year":"2024","unstructured":"Paul J et al (2024) Overlapping and non-overlapping indications for checkpoint inhibitors in the US. J Clin Oncol 42(16_suppl):11057\u201311057","journal-title":"J Clin Oncol"},{"issue":"8","key":"10054_CR4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik J (2022) Nivolumab plus relatlimab: first approval. Drugs 82(8):925\u2013931","journal-title":"Drugs"},{"issue":"7","key":"10054_CR5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","volume":"21","author":"S Upadhaya","year":"2022","unstructured":"Upadhaya S (2022) Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape. Nat Rev Drug Discov 21(7):482\u2013483","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10054_CR6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","volume":"85","author":"HT Quach","year":"2021","unstructured":"Quach HT (2021) Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol 85(4):956\u2013966","journal-title":"J Am Acad Dermatol"},{"key":"10054_CR7","volume":"14","author":"T Watanabe","year":"2023","unstructured":"Watanabe T, Yamaguchi Y (2023) Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol 14:1071983","journal-title":"Front Immunol"},{"issue":"36","key":"10054_CR8","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126","journal-title":"J Clin Oncol"},{"issue":"10","key":"10054_CR9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","volume":"159","author":"Y Du","year":"2023","unstructured":"Du Y (2023) Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment: a systematic review and meta-analysis. JAMA Dermatol 159(10):1093\u20131101","journal-title":"JAMA Dermatol"},{"key":"10054_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001935","author":"M Kalinich","year":"2021","unstructured":"Kalinich M (2021) Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001935","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10054_CR11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN et al (2020) Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 83(5):1255\u20131268","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"10054_CR12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V (2018) Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 19(Suppl 1):31\u201339","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10054_CR13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000277656","volume":"33","author":"JC Hassel","year":"2010","unstructured":"Hassel JC (2010) Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie 33(3):94\u201398","journal-title":"Onkologie"},{"issue":"3","key":"10054_CR14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/bjd.20074","volume":"185","author":"LL Thompson","year":"2021","unstructured":"Thompson LL (2021) Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. Br J Dermatol 185(3):627\u2013635","journal-title":"Br J Dermatol"},{"issue":"30","key":"10054_CR15","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","volume":"37","author":"GS Phillips","year":"2019","unstructured":"Phillips GS et al (2019) Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol 37(30):2746\u20132758","journal-title":"J Clin Oncol"},{"key":"10054_CR16","unstructured":"Arnold DL, Krishnamurthy K (2025) Lichen Planus. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526126\/"},{"issue":"2","key":"10054_CR17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","volume":"39","author":"MT Tetzlaff","year":"2017","unstructured":"Tetzlaff MT (2017) Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am J Dermatopathol 39(2):121\u2013129","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10054_CR18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 19(3):345\u2013361","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10054_CR19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","volume":"43","author":"KB Schaberg","year":"2016","unstructured":"Schaberg KB et al (2016) Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 43(4):339\u2013346","journal-title":"J Cutan Pathol"},{"issue":"10","key":"10054_CR20","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","volume":"152","author":"VJ Shi","year":"2016","unstructured":"Shi VJ (2016) Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 152(10):1128\u20131136","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10054_CR21","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1111\/jdv.14284","volume":"31","author":"V Sibaud","year":"2017","unstructured":"Sibaud V (2017) Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: clinicopathological findings. J Eur Acad Dermatol Venereol 31(10):e464\u2013e469","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10054_CR22","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","volume":"80","author":"E Coleman","year":"2019","unstructured":"Coleman E et al (2019) Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol 80(4):990\u2013997","journal-title":"J Am Acad Dermatol"},{"key":"10054_CR23","doi-asserted-by":"crossref","unstructured":"Hwang SJ et al (2016)\u00a0Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol\u00a074(3):455\u201361 e1","DOI":"10.1016\/j.jaad.2015.10.029"},{"key":"10054_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-254692","author":"BJ McCormick","year":"2023","unstructured":"McCormick BJ (2023) Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2023-254692","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10054_CR25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamaoncol.2021.4318","volume":"8","author":"ER Nadelmann","year":"2022","unstructured":"Nadelmann ER, Yeh JE, Chen ST (2022) Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: a systematic review. JAMA Oncol 8(1):130\u2013138","journal-title":"JAMA Oncol"},{"issue":"5","key":"10054_CR26","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","volume":"84","author":"V Nikolaou","year":"2021","unstructured":"Nikolaou V (2021) Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. J Am Acad Dermatol 84(5):1310\u20131320","journal-title":"J Am Acad Dermatol"},{"key":"10054_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010088","author":"AM Eshaq","year":"2024","unstructured":"Eshaq AM (2024) Immune checkpoint inhibitor-associated cutaneous adverse events: mechanisms of occurrence. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26010088","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10054_CR28","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/1078-0432.CCR-23-3431","volume":"30","author":"ME Lacouture","year":"2024","unstructured":"Lacouture ME et al (2024) Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways. Clin Cancer Res 30(13):2822\u20132834","journal-title":"Clin Cancer Res"},{"key":"10054_CR29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2021.100506","volume":"30","author":"WM Masterson","year":"2022","unstructured":"Masterson WM (2022) A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution. Cancer Treatment and Research Communications 30:100506","journal-title":"Cancer Treatment and Research Communications"},{"key":"10054_CR30","unstructured":"Thompson JA et al (2024)\u00a0NCCN Guidelines(R) Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw\u00a022(9):582\u2013592"},{"issue":"21","key":"10054_CR31","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","volume":"27","author":"X Bai","year":"2021","unstructured":"Bai X et al (2021) Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. Clin Cancer Res 27(21):5993\u20136000","journal-title":"Clin Cancer Res"},{"key":"10054_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002261","author":"DV Maslov","year":"2021","unstructured":"Maslov DV (2021) Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-002261","journal-title":"J Immunother Cancer"},{"key":"10054_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215297","author":"Y Guo","year":"2022","unstructured":"Guo Y et al (2022) Focus on the dynamics of neutrophil-to-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14215297","journal-title":"Cancers (Basel)"},{"key":"10054_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdin.2021.12.003","volume":"7","author":"A Abduelmula","year":"2022","unstructured":"Abduelmula A (2022) Immune checkpoint inhibitor induced lichenoid reactions: a systematic review of characteristics and treatment outcomes. JAAD Int 7:1\u20136","journal-title":"JAAD Int"},{"issue":"1","key":"10054_CR35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","volume":"25","author":"A Muntyanu","year":"2021","unstructured":"Muntyanu A et al (2021) Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management [Formula: see text]. J Cutan Med Surg 25(1):59\u201376","journal-title":"J Cutan Med Surg"},{"key":"10054_CR36","doi-asserted-by":"crossref","unstructured":"Varma A, Friedlander P, De Moll EH, Desman G, Levitt J (2020) Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate. Dermatol Online J 26(5)","DOI":"10.5070\/D3265048774"},{"issue":"6","key":"10054_CR37","first-page":"397","volume":"2","author":"L Kou","year":"2021","unstructured":"Kou L et al (2021) Steroid-refractory lichenoid eruption associated with Pembrolizumab in a patient with non-small cell lung cancer. HCA Healthc J Med 2(6):397\u2013400","journal-title":"HCA Healthc J Med"},{"key":"10054_CR38","unstructured":"Hanoodi M, Mittal M (2024) Methotrexate. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556114\/"},{"key":"10054_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60071024","author":"M Mocanu","year":"2024","unstructured":"Mocanu M (2024) An overview of Methotrexate indications in skin diseases. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina60071024","journal-title":"Medicina (Kaunas)"},{"issue":"7","key":"10054_CR40","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1080\/09546634.2022.2104446","volume":"33","author":"NA Gamal Alsakaan","year":"2022","unstructured":"Gamal Alsakaan NA et al (2022) Efficacy and safety of oral methotrexate versus oral mini pulse betamethasone therapy in the treatment of lichen planus: a comparative study. J Dermatolog Treat 33(7):3039\u20133046","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10054_CR41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/DER.0000000000000776","volume":"34","author":"AM Brown","year":"2023","unstructured":"Brown AM et al (2023) Systemic treatment of cutaneous adverse events after immune checkpoint inhibitor therapy: a review. Dermatitis\u00ae 34(3):201\u2013208","journal-title":"Dermatitis\u00ae"},{"issue":"4","key":"10054_CR42","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/09546634.2021.1937476","volume":"33","author":"T Hajar","year":"2022","unstructured":"Hajar T (2022) Low-dose methotrexate in dermatology: the utility of serological monitoring in a real-world cohort. J Dermatolog Treat 33(4):2161\u20132167","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"10054_CR43","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2230.2012.04440.x","volume":"37","author":"S Dogra","year":"2012","unstructured":"Dogra S, Krishna V, Kanwar AJ (2012) Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study. Clin Exp Dermatol 37(7):729\u2013734","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10054_CR44","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1111\/j.1468-3083.2012.04654.x","volume":"27","author":"AJ Kanwar","year":"2013","unstructured":"Kanwar AJ, De D (2013) Methotrexate for treatment of lichen planus: old drug, new indication. J Eur Acad Dermatol Venereol 27(3):e410\u2013e413","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10054_CR45","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.928390","volume":"12","author":"S Bruera","year":"2022","unstructured":"Bruera S, Suarez-Almazor ME (2022) The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Front Oncol 12:928390","journal-title":"Front Oncol"},{"key":"10054_CR46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jdcr.2024.09.019","volume":"54","author":"EL Myers","year":"2024","unstructured":"Myers EL, Googe PB, Culton DA (2024) Treatment of immune checkpoint inhibitor-induced bullous pemphigoid with methotrexate. JAAD Case Rep 54:31\u201336","journal-title":"JAAD Case Rep"},{"key":"10054_CR47","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1404a220","author":"A Khurana","year":"2024","unstructured":"Khurana A, Sharath S, Sardana K (2024) Efficacy and safety of low-dose methotrexate in generalized and recalcitrant lichen planus: a retrospective study at a tertiary care center. Dermatology Practical & Conceptual. https:\/\/doi.org\/10.5826\/dpc.1404a220","journal-title":"Dermatology Practical & Conceptual"},{"issue":"6","key":"10054_CR48","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A (2020) Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 82(6):1445\u20131486","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10054_CR49","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/ced.13410","volume":"43","author":"C Edwards","year":"2018","unstructured":"Edwards C, Fearfield L (2018) Nivolumab-induced lichenoid dermatitis occurring in a patient with metastatic melanoma successfully treated with alitretinoin. Clin Exp Dermatol 43(5):609\u2013610","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10054_CR50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/idoj.idoj_377_22","volume":"14","author":"A Bansal","year":"2023","unstructured":"Bansal A et al (2023) Pembrolizumab-induced lichen planus: a rare immune-related adverse side effect. Indian Dermatol Online J 14(3):391\u2013394","journal-title":"Indian Dermatol Online J"},{"key":"10054_CR51","first-page":"1","volume":"23","author":"AK Lindner","year":"2019","unstructured":"Lindner AK (2019) Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - a case report. Urol Case Rep 23:1\u20132","journal-title":"Urol Case Rep"},{"issue":"2","key":"10054_CR52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.14192","volume":"65","author":"K Truong","year":"2024","unstructured":"Truong K (2024) Immune checkpoint inhibitor-induced lichenoid drug eruption-sparing scar burns. Australas J Dermatol 65(2):163\u2013166","journal-title":"Australas J Dermatol"},{"issue":"2","key":"10054_CR53","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/odi.13218","volume":"26","author":"MA Shazib","year":"2020","unstructured":"Shazib MA (2020) Oral immune-related adverse events associated with PD-1 inhibitor therapy: a case series. Oral Dis 26(2):325\u2013333","journal-title":"Oral Dis"},{"issue":"4","key":"10054_CR54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CMR.0000000000000263","volume":"26","author":"DV Wakade","year":"2016","unstructured":"Wakade DV et al (2016) PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. Melanoma Res 26(4):421\u2013424","journal-title":"Melanoma Res"},{"issue":"4","key":"10054_CR55","first-page":"301","volume":"68","author":"AS Boyd","year":"2001","unstructured":"Boyd AS, King LE (2001) Lichenoid drug reaction from isotretinoin therapy. Cutis 68(4):301\u2013303","journal-title":"Cutis"},{"issue":"3","key":"10054_CR56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/dth.12337","volume":"29","author":"A Alamri","year":"2016","unstructured":"Alamri A et al (2016) Hypertrophic lichen planus - successful treatment with acitretin. Dermatol Ther 29(3):173\u2013176","journal-title":"Dermatol Ther"},{"key":"10054_CR57","doi-asserted-by":"crossref","unstructured":"Laurberg G et al (1991)\u00a0Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol 24(3):434\u2013437","DOI":"10.1016\/0190-9622(91)70067-C"},{"key":"10054_CR58","unstructured":"Zito PM, Patel P, Mazzoni T (2024) Acitretin. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519571\/"},{"key":"10054_CR59","doi-asserted-by":"crossref","unstructured":"Carretero G et al (2013) Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr\u00a0104(7):598\u2013616","DOI":"10.1016\/j.adengl.2013.01.001"},{"issue":"8","key":"10054_CR60","volume":"14","author":"Y Kost","year":"2022","unstructured":"Kost Y et al (2022) Immune checkpoint inhibitor-induced psoriasiform, spongiotic, and lichenoid dermatitis: a novel clinicopathological pattern. Cureus 14(8):e28010","journal-title":"Cureus"},{"issue":"10","key":"10054_CR61","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1517\/14656566.6.10.1725","volume":"6","author":"CS Lee","year":"2005","unstructured":"Lee CS, Koo J (2005) A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother 6(10):1725\u20131734","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10054_CR62","first-page":"123","volume":"93","author":"IW Tattersall","year":"2020","unstructured":"Tattersall IW, Leventhal JS (2020) Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist. Yale J Biol Med 93(1):123\u2013132","journal-title":"Yale J Biol Med"},{"issue":"3","key":"10054_CR63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/ajd.13660","volume":"62","author":"AK Uthayakumar","year":"2021","unstructured":"Uthayakumar AK et al (2021) Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma. Australas J Dermatol 62(3):403\u2013406","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10054_CR64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cup.13587","volume":"47","author":"A Coscarart","year":"2020","unstructured":"Coscarart A (2020) Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus. J Cutan Pathol 47(3):275\u2013279","journal-title":"J Cutan Pathol"},{"key":"10054_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.08.042","author":"ZC Ney","year":"2024","unstructured":"Ney ZC, Nicholson LT, Madigan LM (2024) Immunotherapy-associated lichen planus pemphigoides successfully treated with intravenous immune globulin\u2014two illustrative cases. JAAD Case Rep. https:\/\/doi.org\/10.1016\/j.jdcr.2024.08.042","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10054_CR66","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1111\/ajd.14223","volume":"65","author":"VA Headd","year":"2024","unstructured":"Headd VA (2024) Nivolumab-induced lichenoid penile ulceration and re-emergent mucocutaneous eruption treated with hydroxychloroquine. Australas J Dermatol 65(4):e97\u2013e99","journal-title":"Australas J Dermatol"},{"key":"10054_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.11.010","author":"NF Alnajjar","year":"2025","unstructured":"Alnajjar NF, Tahan SR, Iriarte C (2025) Immunotherapy-associated bullous and oral erosive lichenoid eruption successfully treated with hydroxychloroquine. JAAD Case Rep. https:\/\/doi.org\/10.1016\/j.jdcr.2024.11.010","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10054_CR68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/ijdr.IJDR_943_20","volume":"32","author":"SC Raj","year":"2021","unstructured":"Raj SC (2021) Hydroxychloroquine- a new treatment option for erosive oral lichen planus. Indian J Dent Res 32(2):192\u2013198","journal-title":"Indian J Dent Res"},{"key":"10054_CR69","doi-asserted-by":"crossref","unstructured":"In 't Veld AE et al (2023) Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study. Immunol Res\u00a071(4):617\u2013627","DOI":"10.1007\/s12026-023-09367-3"},{"issue":"6","key":"10054_CR70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251731","volume":"16","author":"J Krueger","year":"2021","unstructured":"Krueger J (2021) Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. PLoS ONE 16(6):e0251731","journal-title":"PLoS ONE"},{"issue":"1","key":"10054_CR71","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101990","volume":"24","author":"S Wabitsch","year":"2021","unstructured":"Wabitsch S et al (2021) Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models. iScience 24(1):101990","journal-title":"iScience"},{"issue":"1","key":"10054_CR72","volume":"9","author":"P Liu","year":"2020","unstructured":"Liu P et al (2020) Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. Oncoimmunology 9(1):1789284","journal-title":"Oncoimmunology"},{"issue":"5","key":"10054_CR73","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","volume":"38","author":"J Roberts","year":"2019","unstructured":"Roberts J et al (2019) Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin Rheumatol 38(5):1513\u20131519","journal-title":"Clin Rheumatol"},{"key":"10054_CR74","doi-asserted-by":"crossref","unstructured":"Vitzthum von Eckstaedt H, Singh A, Reid P, Trotter K (2024) Immune checkpoint inhibitors and lupus erythematosus. Pharmaceuticals 17(2):252","DOI":"10.3390\/ph17020252"},{"key":"10054_CR75","doi-asserted-by":"crossref","first-page":"adv40801","DOI":"10.2340\/actadv.v104.40801","volume":"104","author":"D Pogorelov","year":"2024","unstructured":"Pogorelov D et al (2024) Novel onset of cutaneous lupus erythematosus induced by Pembrolizumab. Acta Derm Venereol 104:adv40801","journal-title":"Acta Derm Venereol"},{"key":"10054_CR76","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1334718","volume":"11","author":"A Khorasanchi","year":"2024","unstructured":"Khorasanchi A (2024) Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature. Front Med 11:1334718","journal-title":"Front Med"},{"issue":"4","key":"10054_CR77","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.oooo.2023.12.007","volume":"137","author":"P Chirravur","year":"2024","unstructured":"Chirravur P et al (2024) Hydroxychloroquine for the management of recalcitrant oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol 137(4):355\u2013361","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"4","key":"10054_CR78","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0190-9622(93)70082-5","volume":"28","author":"D Eisen","year":"1993","unstructured":"Eisen D (1993) Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial. J Am Acad Dermatol 28(4):609\u2013612","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10054_CR79","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1111\/odi.14746","volume":"30","author":"Y Xie","year":"2024","unstructured":"Xie Y et al (2024) Hydroxychloroquine is effective in oral lichen planus: a multicenter, randomized, controlled trial. Oral Dis 30(5):3126\u20133135","journal-title":"Oral Dis"},{"issue":"6","key":"10054_CR80","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123(6):1386\u20131394","journal-title":"Ophthalmology"},{"key":"10054_CR81","unstructured":"Stokkermans TJ, Falkowitz DM, Trichonas G (2024) Chloroquine and Hydroxychloroquine Toxicity. StatPearls, Treasure Island"},{"issue":"5","key":"10054_CR82","doi-asserted-by":"crossref","DOI":"10.1007\/s00403-024-02876-7","volume":"316","author":"M Green","year":"2024","unstructured":"Green M (2024) Utility of hydroxychloroquine laboratory monitoring in dermatologic and rheumatologic patients. Arch Dermatol Res 316(5):194","journal-title":"Arch Dermatol Res"},{"key":"10054_CR83","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes Lupus Nephritis Work, KDIGO G (2024) Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int 105(1S):S1-S69","DOI":"10.1016\/j.kint.2023.09.002"},{"key":"10054_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007324","author":"AM Kuo","year":"2023","unstructured":"Kuo AM et al (2023) Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-007324","journal-title":"J Immunother Cancer"},{"key":"10054_CR85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2023.05.004","volume":"37","author":"JJ Park","year":"2023","unstructured":"Park JJ et al (2023) Pembrolizumab-induced lichenoid dermatitis treated with dupilumab. JAAD Case Rep 37:13\u201315","journal-title":"JAAD Case Rep"},{"key":"10054_CR86","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jdcr.2023.05.036","volume":"38","author":"SK Zemlok","year":"2023","unstructured":"Zemlok SK et al (2023) Nivolumab-induced lichen planus responsive to dupilumab treatment in a patient with stage III C melanoma. JAAD Case Rep 38:23\u201326","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10054_CR87","first-page":"E8","volume":"107","author":"BT Pousti","year":"2021","unstructured":"Pousti BT et al (2021) Dupilumab for the treatment of lichen planus. Cutis 107(4):E8\u2013E10","journal-title":"Cutis"},{"issue":"3","key":"10054_CR88","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000527918","volume":"14","author":"L Kern","year":"2022","unstructured":"Kern L (2022) Dupilumab-induced lichen planus: a case with oral and cutaneous eruptions. Case Rep Dermatol 14(3):356\u2013361","journal-title":"Case Rep Dermatol"},{"issue":"7","key":"10054_CR89","volume":"15","author":"FA Gajraj","year":"2023","unstructured":"Gajraj FA et al (2023) A case report and literature review of the role of dupilumab in the management of lichen planus: cause or treatment? Cureus 15(7):e41274","journal-title":"Cureus"},{"key":"10054_CR90","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2022.12.013","volume":"33","author":"Z Rehan","year":"2023","unstructured":"Rehan Z (2023) Lichenoid-granulomatous drug reactions to dupilumab: a report of 2 cases. JAAD Case Rep 33:13\u201316","journal-title":"JAAD Case Rep"},{"key":"10054_CR91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdcr.2021.04.035","volume":"13","author":"TE Kim","year":"2021","unstructured":"Kim TE, Shin MK (2021) De novo case of lichenoid eruption following dupilumab treatment. JAAD Case Rep 13:71\u201372","journal-title":"JAAD Case Rep"},{"key":"10054_CR92","unstructured":"Gade A, Ghani H, Patel P, Rubenstein R (2024) Dupilumab. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585114\/"},{"issue":"5","key":"10054_CR93","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A (2020) Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 182(5):1120\u20131135","journal-title":"Br J Dermatol"},{"issue":"6","key":"10054_CR94","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaad.2022.08.001","volume":"87","author":"D Bur","year":"2022","unstructured":"Bur D et al (2022) A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes. J Am Acad Dermatol 87(6):1394\u20131395","journal-title":"J Am Acad Dermatol"},{"key":"10054_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2023.09.041","volume":"43","author":"JN Young","year":"2024","unstructured":"Young JN et al (2024) The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: a single-institution real-life study. JAAD Case Rep 43:1\u20133","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10054_CR96","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46540-0","volume":"15","author":"C Bangert","year":"2024","unstructured":"Bangert C (2024) Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun 15(1):2839","journal-title":"Nat Commun"},{"issue":"10","key":"10054_CR97","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1111\/ijd.15595","volume":"60","author":"M Dominguez-Santas","year":"2021","unstructured":"Dominguez-Santas M (2021) Avelumab-induced lichen planopilaris, a novel association. Int J Dermatol 60(10):e414\u2013e416","journal-title":"Int J Dermatol"},{"issue":"10","key":"10054_CR98","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1111\/1346-8138.14906","volume":"46","author":"Y Sato","year":"2019","unstructured":"Sato Y (2019) Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab. J Dermatol 46(10):e374\u2013e375","journal-title":"J Dermatol"},{"issue":"5","key":"10054_CR99","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/DAD.0000000000002139","volume":"44","author":"MM Boyle","year":"2022","unstructured":"Boyle MM et al (2022) Lichen planus pemphigoides associated with PD-1 and PD-L1 inhibitors: a case series and review of the literature. Am J Dermatopathol 44(5):360\u2013367","journal-title":"Am J Dermatopathol"},{"issue":"11","key":"10054_CR100","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamadermatol.2024.2722","volume":"160","author":"S Parkinson","year":"2024","unstructured":"Parkinson S et al (2024) Treatment of pembrolizumab-induced mucocutaneous lichen planus with metronidazole. JAMA Dermatol 160(11):1251\u20131252","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10054_CR101","first-page":"742","volume":"15","author":"MI Schmidgen","year":"2017","unstructured":"Schmidgen MI et al (2017) Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 15(7):742\u2013745","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"4","key":"10054_CR102","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2133.2006.07733.x","volume":"156","author":"BM Hantash","year":"2007","unstructured":"Hantash BM, Kanzler MH (2007) The efficacy of tetracycline antibiotics for treatment of lichen planus: an open-label clinical trial. Br J Dermatol 156(4):758\u2013760","journal-title":"Br J Dermatol"},{"issue":"2 Pt 1","key":"10054_CR103","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1067\/mjd.2000.104683","volume":"43","author":"AY Buyuk","year":"2000","unstructured":"Buyuk AY, Kavala M (2000) Oral metronidazole treatment of lichen planus. J Am Acad Dermatol 43(2 Pt 1):260\u2013262","journal-title":"J Am Acad Dermatol"},{"key":"10054_CR104","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01389","volume":"10","author":"F Hubner","year":"2019","unstructured":"Hubner F, Langan EA, Recke A (2019) Lichen planus pemphigoides: from lichenoid inflammation to autoantibody-mediated blistering. Front Immunol 10:1389","journal-title":"Front Immunol"},{"issue":"6","key":"10054_CR105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.21037\/hbsn.2018.11.12","volume":"7","author":"M Yi","year":"2018","unstructured":"Yi M (2018) The role of gut microbiota in immune checkpoint inhibitor therapy. Hepatobiliary Surg Nutr 7(6):481\u2013483","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"12","key":"10054_CR106","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","volume":"5","author":"DJ Pinato","year":"2019","unstructured":"Pinato DJ (2019) Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol 5(12):1774\u20131778","journal-title":"JAMA Oncol"},{"key":"10054_CR107","doi-asserted-by":"crossref","first-page":"1001623","DOI":"10.3389\/fimmu.2022.1001623","volume":"13","author":"G Zhou","year":"2022","unstructured":"Zhou G et al (2022) Interaction between gut microbiota and immune checkpoint inhibitor-related colitis. Front Immunol 13:1001623","journal-title":"Front Immunol"},{"key":"10054_CR108","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1147513","volume":"4","author":"F Muhaj","year":"2023","unstructured":"Muhaj F et al (2023) Mucocutaneous adverse events to immune checkpoint inhibitors. Front Allergy 4:1147513","journal-title":"Front Allergy"},{"issue":"5","key":"10054_CR109","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaad.2020.05.112","volume":"83","author":"S Ravichandran","year":"2020","unstructured":"Ravichandran S, Kheterpal MK (2020) Apremilast for the off-label treatment of lichenoid and interface dermatoses. J Am Acad Dermatol 83(5):1489\u20131491","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10054_CR110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2012.07.014","volume":"68","author":"J Paul","year":"2013","unstructured":"Paul J (2013) An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series. J Am Acad Dermatol 68(2):255\u2013261","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10054_CR111","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5826\/dpc.0904a11","volume":"9","author":"Z Apalla","year":"2019","unstructured":"Apalla Z et al (2019) Psoriasis in patients with active lung cancer: is Apremilast a safe option? Dermatol Pract Concept 9(4):300\u2013301","journal-title":"Dermatol Pract Concept"},{"key":"10054_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60030373","author":"LG Popa","year":"2024","unstructured":"Popa LG (2024) Perspectives on psoriasiform adverse events from immune checkpoint inhibitors: lessons learned from our practice. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina60030373","journal-title":"Medicina (Kaunas)"},{"key":"10054_CR113","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jdcr.2021.03.015","volume":"11","author":"A Mayor Ibarguren","year":"2021","unstructured":"Mayor Ibarguren A et al (2021) Apremilast for immune checkpoint inhibitor-induced psoriasis: a case series. JAAD Case Rep 11:84\u201389","journal-title":"JAAD Case Rep"},{"key":"10054_CR114","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jdrv.2024.10.007","volume":"2","author":"M Kaur","year":"2024","unstructured":"Kaur M (2024) Apremilast for immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis: a systematic review. JAAD Rev 2:149\u2013152","journal-title":"JAAD Rev"},{"key":"10054_CR115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.579445","volume":"10","author":"MA Siciliano","year":"2020","unstructured":"Siciliano MA et al (2020) Pembrolizumab-induced psoriasis in metastatic melanoma: activity and safety of apremilast, a case report. Front Oncol 10:579445","journal-title":"Front Oncol"},{"key":"10054_CR116","unstructured":"Padda IS, Bhatt R, Parmar M (2025) Apremilast. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572078\/"},{"issue":"8","key":"10054_CR117","first-page":"358","volume":"17","author":"JG Hashash","year":"2021","unstructured":"Hashash JG, Francis FF, Farraye FA (2021) Diagnosis and management of immune checkpoint inhibitor colitis. Gastroenterol Hepatol (N Y) 17(8):358\u2013366","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"6","key":"10054_CR118","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5582\/ddt.2018.01069","volume":"12","author":"B Mallick","year":"2018","unstructured":"Mallick B (2018) Apremilast induced chronic diarrhea and malnutrition. Drug Discov Ther 12(6):379\u2013380","journal-title":"Drug Discov Ther"},{"issue":"4","key":"10054_CR119","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-024-00866-z","volume":"25","author":"J Pach","year":"2024","unstructured":"Pach J et al (2024) The use of biologic agents for the treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors: a review of reported cases. Am J Clin Dermatol 25(4):595\u2013607","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10054_CR120","first-page":"989","volume":"30","author":"JJ Lo","year":"2022","unstructured":"Lo JJ et al (2022) Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients. Support Care Cancer 30(2):989\u2013994","journal-title":"Support Care Cancer"},{"issue":"3","key":"10054_CR121","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1889449","volume":"18","author":"P Sollena","year":"2022","unstructured":"Sollena P et al (2022) \u201cSkin rashes\u201d and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management. Hum Vaccin Immunother 18(3):1889449","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10054_CR122","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2023.10.012","volume":"90","author":"F Alamon-Reig","year":"2024","unstructured":"Alamon-Reig F et al (2024) Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: a retrospective cohort from the European Task Force of Dermatology for Cancer patients. J Am Acad Dermatol 90(2):429\u2013432","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10054_CR123","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13555-022-00860-5","volume":"13","author":"R Mital","year":"2023","unstructured":"Mital R et al (2023) Novel and off-label biologic use in the management of hidradenitis suppurativa, pyoderma gangrenosum, lichen planus, and seborrheic dermatitis: a narrative review. Dermatol Ther (Heidelb) 13(1):77\u201394","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"10054_CR124","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00011-023-01763-7","volume":"72","author":"S Afzali","year":"2023","unstructured":"Afzali S (2023) The potential roles of Th17 cells in the pathogenesis of oral lichen planus. Inflamm Res 72(7):1513\u20131524","journal-title":"Inflamm Res"},{"issue":"1","key":"10054_CR125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jop.12142","volume":"44","author":"R Lu","year":"2015","unstructured":"Lu R et al (2015) Inflammation-related cytokines in oral lichen planus: an overview. J Oral Pathol Med 44(1):1\u201314","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"10054_CR126","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bjd.16003","volume":"178","author":"R Maglie","year":"2018","unstructured":"Maglie R et al (2018) Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment. Br J Dermatol 178(1):303\u2013304","journal-title":"Br J Dermatol"},{"issue":"4","key":"10054_CR127","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/1346-8138.13637","volume":"44","author":"T Komori","year":"2017","unstructured":"Komori T et al (2017) Oral lichen planus associated with candidiasis during secukinumab treatment. J Dermatol 44(4):e60\u2013e61","journal-title":"J Dermatol"},{"key":"10054_CR128","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001399","author":"H Zhang","year":"2021","unstructured":"Zhang H et al (2021) Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2020-001399","journal-title":"RMD Open"},{"key":"10054_CR129","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fimmu.2018.00444","volume":"9","author":"BL Salomon","year":"2018","unstructured":"Salomon BL et al (2018) Tumor necrosis factor alpha and regulatory T cells in oncoimmunology. Front Immunol 9:444","journal-title":"Front Immunol"},{"issue":"7","key":"10054_CR130","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/ard-2023-223885","volume":"82","author":"AR Bass","year":"2023","unstructured":"Bass AR (2023) Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis 82(7):920\u2013926","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10054_CR131","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/1346-8138.14205","volume":"45","author":"K Obara","year":"2018","unstructured":"Obara K, Masuzawa M, Amoh Y (2018) Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: a report of two cases and published work review. J Dermatol 45(5):587\u2013591","journal-title":"J Dermatol"},{"key":"10054_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194781","author":"S Elad","year":"2023","unstructured":"Elad S, Yarom N, Zadik Y (2023) Immunotherapy-related oral adverse effects: immediate sequelae, chronicity and secondary cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15194781","journal-title":"Cancers (Basel)"},{"key":"10054_CR133","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jdcr.2023.05.013","volume":"37","author":"P Kim-Lim","year":"2023","unstructured":"Kim-Lim P, Thomas C (2023) Crushed apremilast for the treatment of oral lichen planus. JAAD Case Rep 37:114\u2013115","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10054_CR134","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/odi.13964","volume":"28","author":"BA Klein","year":"2022","unstructured":"Klein BA et al (2022) Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Oral Dis 28(1):9\u201322","journal-title":"Oral Dis"},{"key":"10054_CR135","unstructured":"Gheorghe C et al (2014) Association of oral lichen planus with chronic C hepatitis. Review of the data in literature. Maedica (Bucur)\u00a09(1):98\u2013103"},{"issue":"1","key":"10054_CR136","first-page":"3","volume":"4","author":"M Boorghani","year":"2010","unstructured":"Boorghani M et al (2010) Oral lichen planus: clinical features, etiology, treatment and management; a review of literature. J Dent Res Dent Clin Dent Prospects 4(1):3\u20139","journal-title":"J Dent Res Dent Clin Dent Prospects"},{"issue":"6","key":"10054_CR137","doi-asserted-by":"crossref","first-page":"659","DOI":"10.5858\/arpa.2022-0515-RA","volume":"148","author":"CP Whittington","year":"2024","unstructured":"Whittington CP (2024) Hypertrophic lichen planus: an up-to-date review and differential diagnosis. Arch Pathol Lab Med 148(6):659\u2013665","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"10054_CR138","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/cup.12275","volume":"41","author":"A Alomari","year":"2014","unstructured":"Alomari A, McNiff JM (2014) The significance of eosinophils in hypertrophic lichen planus. J Cutan Pathol 41(4):347\u2013352","journal-title":"J Cutan Pathol"},{"issue":"5","key":"10054_CR139","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1634\/theoncologist.2019-0796","volume":"25","author":"AH Ameri","year":"2020","unstructured":"Ameri AH et al (2020) Hypertrophic lichen planus with histological features of squamous cell carcinoma associated with immune checkpoint blockade therapy. Oncologist 25(5):366\u2013368","journal-title":"Oncologist"},{"issue":"12","key":"10054_CR140","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/DSS.0000000000000565","volume":"41","author":"TJ Knackstedt","year":"2015","unstructured":"Knackstedt TJ (2015) Squamous cell carcinoma arising in hypertrophic lichen planus: a review and analysis of 38 cases. Dermatol Surg 41(12):1411\u20131418","journal-title":"Dermatol Surg"},{"issue":"5","key":"10054_CR141","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.3390\/curroncol30050342","volume":"30","author":"SWS Chan","year":"2023","unstructured":"Chan SWS et al (2023) Immune-checkpoint induced skin toxicity masked as squamous cell carcinoma: case report on mimickers of dermatological toxicity with PD-1 inhibition. Curr Oncol 30(5):4527\u20134537","journal-title":"Curr Oncol"},{"key":"10054_CR142","doi-asserted-by":"crossref","unstructured":"Gorouhi F, Firooz A, Khatami A, Ladoyanni E, Bouzari N, Kamangar F, Gill JK (2018) Interventions for cutaneous lichen planus.\u00a0Cochrane Database Syst Rev 2018(5):CD008038","DOI":"10.1002\/14651858.CD008038.pub2"},{"issue":"8","key":"10054_CR143","volume":"15","author":"Y Tembunde","year":"2023","unstructured":"Tembunde Y, Dika MN (2023) Pembrolizumab-induced eruptive keratoacanthomas and lichen planus in a lung cancer patient. Cureus 15(8):e43402","journal-title":"Cureus"},{"issue":"10","key":"10054_CR144","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/cup.13739","volume":"47","author":"ML Marques-Piubelli","year":"2020","unstructured":"Marques-Piubelli ML (2020) Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: a diagnostic pitfall for superficially invasive squamous cell carcinoma. J Cutan Pathol 47(10):954\u2013959","journal-title":"J Cutan Pathol"},{"issue":"2","key":"10054_CR145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40268-024-00461-x","volume":"24","author":"O Lim","year":"2024","unstructured":"Lim O, Maher E, Miller DD (2024) PD-1 inhibitor induced hypertrophic lichen planus: a case report. Drugs R D 24(2):353\u2013357","journal-title":"Drugs R D"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10054-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10054-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10054-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T13:03:30Z","timestamp":1763211810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10054-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":145,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10054"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10054-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as this is a literature review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patients provided informed consent regarding publishing their photographs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"985"}}